Table 4.
Outcomes of included clinical studies.
| Abbreviation ID of Study, Authors, Year, Reference | Clinical Success | Microbiological Success | Mortality | Adverse Events | ||||
|---|---|---|---|---|---|---|---|---|
| Minocycline (%) | Other Antibiotics (%) |
Minocycline (%) |
Other Antibiotics (%) | Minocycline (%) |
Other Antibiotics (%) | Minocycline (%) |
Other Antibiotics (%) |
|
| Study A, Bishburg E. et al., 2014 [32] | 5 (100) BSI: 1 (100)LRTI: 2 (100) |
n/a | Not available | n/a | 0 |
n/a | Not available | n/a |
| Study B, Chan J.D. et al., 2010[33] | 29 (80.5) VAP: 29 (80.5) |
13 (68.4) | Not separately specified * | Not separately specified * | Not separately specified * | Not separately specified * | 0 |
Nephrotoxicity due to aminoglycosides or polymyxins: 10 (18.2) |
| Study C, Goff D.A. et al., 2014 [34] | 40 (72.7) LRTI: 20 (62.5) § BSI: 9 (90) § LRTI+BSI: 3 (75) § |
n/a | 43 (78) ± | n/a | 14 (25.5) |
n/a | 0 |
n/a |
| Study D, Griffith M.E. et al., 2008 [35] | 7 (87.5) | n/a | Not available | n/a | 0 | n/a | Eosinophilia & neutropenia: 1 (12.5) | n/a |
| Study E, Ning F. et al., 2014 [36] | 9 (100) LRTI: 3 (100) LRTI + SSTI: 2 (100) LRTI + SSTI + BSI: 4 (100) |
n/a | 8 (88.9) ± | n/a | 0 | n/a | 0 | n/a |
| Study F, Pogue J.M. et al., 2014 [37] | 5 (71.4) LRTI: 1 (50) BSI: 2 (66.6) LRTI + SSTI: 1 (100) LRTI + BSI: 1 (100) |
n/a | 3 (60) ** LRTI + BSI: 1 (100) BSI: 2 (66.6) |
n/a | 2 (28.6) | n/a | Nephrotoxicity due to colistin combination: 2 (28.6) |
n/a |
| Study G, Shi Y. et al., 2012 [38] | 48 (62.3) ± | n/a | 36 (46.8) ± | n/a | 19 (24.7) | n/a | Elevation of LFTs: 6 (7.8) |
n/a |
| Study H, Wang L.W. et al., 2014 [39] | 13 (65) VAP: 13 (65) |
5 (22.7) VAP: 5 (22.7) |
8 (40) VAP: 8 (40) |
3 (13.6) VAP: 3 (13.6) |
Not available | Not available | Not available | Not available |
| Study I, Wood G.C. et al., 2003 [40] | 4 (100) VAP: 4 (100) ± |
2 (66.7) VAP: 2 (66.7) ± |
3 (100) ** VAP: 3 (100) ± |
1 (50) ** VAP: 1 (50) ± |
0 | 1 (33.3) | 0 | 0 |
| Study J, Vila A. et al., 2016 [41] | 2 (100) | 1 (100) | 2 (100) | 1 (100) | 0 | 0 | 0 | 0 |
* Data were not available for “Minocycline group” and “Other Antibiotics” group separately. ** Percentages were calculated for patients with available data. § Data were not available for 1 patient with clinical failure. ± Data were not available for all types of infections separately. BSI: Bloodstream Infection, LFTs: Liver function tests, LRTI: Lower respiratory tract infection, n/a: not applicable data, SSTI: Skin and soft tissue infection, VAP: Ventilator-associated pneumonia.